The WM3899 cell line, which harbors a similar exon 11 B-Raf mutation and was sensitive to pazopanib in vitro, was also highly sensitive to pazopanib in vivo, with 62% and 67% decreases in tumor size 7 days after treatment at 30 and 100 mg/kg drug, respectively (p = 0.002 and p = 0.0002, respectively). Here, BRAF is linked to neoplasm.